Amanda McIver

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

A. Jakubowiak, T. Zimmerman, T. Karrison, 2019, British journal of haematology.

Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Megan F. Whelan, K. Griffith, A. Jakubowiak, 2020 .

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

K. Griffith, A. Jakubowiak, R. Vij, 2017 .

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

A. Jakubowiak, A. Stefka, B. Derman, 2021, Blood Cancer Journal.

Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT.

A. Jakubowiak, A. Stefka, B. Derman, 2020 .